BioMarin Pharmaceutical Inc.
BMRN | NASDAQ
$63.87
-$0.19 (-0.30%)
Sep 22, 2026, 2:34 PM ET · Market open
Market Data
Market Cap $12.38B
Enterprise Value $15.71B
Beta 0.24
Average Volume 2.11M
Shares Outstanding (Diluted) 194.15M
Shares Change YoY -1.27%
Institutional Ownership 95.42%
Exchange NASDAQ
ISIN US09061G1013
Price Performance
Price Change 1M -3.8%
Price Change 3M 13.4%
Price Change 6M 15.2%
Price Change YTD 7.8%
Price Change 1Y 18.8%
Price Change 3Y -25.9%
Price Change 5Y -18.5%
1M CAGR (ann.) 0.4%
1Y CAGR (ann.) 16.2%
5Y CAGR (ann.) -3.9%
All-Time CAGR 7.2%
Valuation
PE Ratio 164.26
Forward PE 9.50
PEG Ratio -1.89
Forward PEG 5.18
PS Ratio 3.63
Forward PS 2.80
PB Ratio 1.96
P/FCF Ratio 13.20
P/Adj. FCF Ratio 18.23
P/OCF Ratio 14.43
EV/Sales 4.61
EV/EBIT 145.40
EV/EBITDA 136.44
EV/FCF 16.75
Earnings Yield 0.6%
FCF Yield 7.6%
Adj. FCF Yield 5.5%
Financial Health
Net Debt $3.31B
Total Debt $4.2B
Cash & Short-Term Investments $874.01M
Total Assets $11.72B
Current Ratio 2.39
Quick Ratio 1.32
Debt / Equity Ratio 0.66
Debt / EBITDA 36.50
Debt / FCF 4.48
OCF / Debt 0.26
Interest Coverage 3.27
Altman Z-Score 1.97
Piotroski F-Score 3
Margins & Profitability
Gross Profit Margin 75.5%
Operating Profit Margin 8.0%
EBITDA Margin 11.3%
Net Profit Margin 2.1%
FCF Margin 27.5%
Adj. FCF Margin 19.9%
SBC / Revenue 6.3%
SBC Impact (per share) -27.6%
Returns
Return on Assets 0.6%
Return on Equity 1.2%
Return on Invested Capital 1.3%
Return on Capital Employed 2.7%
Return on Tangible Assets 1.2%
Historical Growth (CAGR)
Revenue CAGR 3Y 15.1%
Revenue CAGR 5Y 12.2%
Revenue CAGR 10Y 13.3%
EPS CAGR 3Y -8.6%
EPS CAGR 5Y -38.1%
EPS CAGR 10Y 34.1%
FCF CAGR 3Y 184.1%
FCF CAGR 5Y 40.6%
FCF CAGR 10Y 77.0%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 41
EPS Growth Next 3Y 186.4%
Revenue Growth Next 3Y 15.5%
Earnings Date Oct 25, 2026
EPS Estimate (next Q) $1.34
EPS Growth Est (next Q) -937.5%
Revenue Est (next Q) $1.02B
Revenue Growth Est (next Q) 31.9%
Fair Value Estimates
Graham Number $16.95
Graham Upside -73.5%
Lynch Fair Value $1.95
Lynch Upside -97.0%
Price Target $90.88
Price Target Upside 41.9%
Cash Flow
Operating Cash Flow $1.08B
Free Cash Flow $937.91M
Adj. Free Cash Flow $679.12M
FCF Per Share $3.80
OCF Per Share $4.44
OCF/S Ratio 25.2%
Income Statement
Revenue $3.41B
Gross Profit $2.57B
Operating Income $273.26M
EBITDA $115.14M
Net Income $72.97M
EPS (Diluted) $0.39
Revenue / Employee $1.06M
Profit / Employee $22.66K
Employees 3,221
Add to Watchlist
Select watchlists to add or remove BMRN